[1]. HEIZMANN C W, ACKERMANN G E, GALICHET A. Pathologies involving the S100 proteins and RAGE[J]. Subcell Biochem, 2007, 45: 93-138.
[2]. LOGSDON C D, FUENTES M K, HUANG E H, et al. RAGE and RAGE ligands in cancer[J]. Curr Mol Med,2007, 7(8): 777-789.
[3]. TESAROVA P, CABINAKOVA M, MIKULOVA V, et al. RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?[J]. Neoplasma, 2015, 62(3): 353-364.
[4]. CHEN R C, YI P P, ZHOU R R, et al. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell line[J]. Mol Cell Biochem, 2014, 390(1-2): 271-280.
[5]. DAHLMANN M, OKHRIMENKO A, MARCINKOWSKI P, et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis[J]. Oncotarget, 2014, 5(10): 3220-3233.
[6]. WANG D, LI T, YE G, et al. Overexpression of the receptor for advanced glycation endproducts (RAGE) is associated with poor prognosis in gastric cancer[J]. PLoS One, 2015, 10(4): e0122697.
[7]. ZHAO C B, BAO J M, LU Y J, et al. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer[J]. Am J Cancer Res, 2014, 4(4): 369-377.
[8]. NASSER M W, WANI N A, AHIRWAR D K, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment[J]. Cancer Res, 2015, 75(6): 974-985.
[9]. LIAO S F, LEE W C, CHEN H C, et al. Baseline human papillomavirus infection, high vaginal parity, and their interaction on cervical cancer risks after a follow-up of more than 10 years[J]. Cancer Causes Control, 2012, 23(5):703-708.
[10]. XU Q, XUE F, YUAN B, et al. The interaction between RAGE gene polymorphisms and HPV infection in determining the susceptibility of cervical cancer in a Chinese population[J]. Cancer Biomarkers 2012, 11(4): 147-153.
[11]. PANG X, ZHANG Y, ZHANG S. High-mobility group box 1 is overexpressed in cervical carcinoma and promotes cell invasion and migration in vitro[J]. Oncol Rep, 2017, 37(2): 831-840.
[12].TIAN T, LI X, HUA Z, et al. S100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial-mesenchymal transition[J]. Oncotarget, 2017, 8(15): 24964-24977.
[13]. 付欣, 王慧玉, 田菁, 等. 晚期糖基化终产物受体RAGE在宫颈鳞癌组织中的表达及临床意义[J]. 中国肿瘤临床, 2011, 38(19): 1201-1204.
[14]. 朱雪洁, 陈慧君, 郑飞云, 等. RAGE在宫颈鳞癌癌变过程中的表达和意义[J]. 浙江医学, 2010, 32(3): 316-319.
[15].郝权, 杜晓琴, 付欣, 等. 高迁移率族蛋白1及晚期糖基化众产物受体在宫颈鳞状细胞癌中的表达及临床意义[J]. 中华肿瘤杂志, 2008, 30(4): 292-295.
[16].GU H, YANG L, SUN Q, et a1. Gly82Ser polymorphism of the receptor for advanced glyeation end products is associated with an increased risk of gastric cancer in a Chinesee population[J]. Clin Cancer Res, 2008, 14(11): 3627-3632.
[17].ZHANG S, HOU X, ZI S, et al. Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in chinese patients[J]. Cell Physiol Biochem, 2013, 31(4-5): 525-531.
[18]. POLJICANIN A, FILIPOVIC N, VUKUSIC PUSIC T, et al. Expression pattern of RAGE and IGF-1 in the human fetal ovary andovarian serous carcinoma[J]. Acta Histochem, 2015, 117(4-5): 468-476.
[19]. RAHIMI F, KARIMI J, GOODARZI M T, et al. Overexpression of receptor for advanced glycation end products (RAGE) in ovarian cancer[J]. Cancer Biomark, 2017, 18(1): 61-68.
[20]. RAI V, TOURÉ F, CHITAYAT S, et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling [J]. J Exp Med, 2012, 209(13): 2339-2350.
[21]. RADIA A M, YASER A M, MA X, et al. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decrease proliferation in human breast cancer cell lines[J]. Int J Mol Sci, 2013, 14(4): 7959-7978.
[22]. YU R L, KI M K, BYEONG H J, et al. Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation[J]. Oncotarget, 2015, 6(27): 23383-23398.
[23]. 鲁凯, 姚壮凯, 刘燕文, 等. RAGE和HMGB1在乳腺癌中表达及其临床意义[J]. 中华肿瘤外科, 2012, 4(6): 352-354.
[24]. 郑立红, 张奇兵, 牛文全, 等. RAGE和MMP-9在乳腺癌组织中的表达及临床相关性研究[J]. 中国妇幼保健, 2015, 30(16): 2645-2648.[24]. YIN C, LI H, ZHANG B, et al. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition[J]. Breast Cancer Res Treat, 2013, 142(2): 297-309.
[25].IOTZOVA-WEISS G, DZIUNYCZ P J, Freiberger S N, et al. S100A8/A9 stimulates keratinocyte proliferation in the development of squamous cell carcinoma of the skin via the receptor for advanced glycation-end products[J]. PLoS One, 2015, 10(3): e0120971.
[26]. STOETZER O J, FERSCHING D M, SALAT C, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemo-therapy[J]. Tumour Biol, 2013, 34(1): 81-90.
[27]. 郑璐, 孟曼, 李彤, 等. 晚期糖基化终末产物受体在人子宫内膜癌中的表达及意义[J]. 现代肿瘤医学, 2016, 24(17): 2670-2673.
[28]. ZHENG L, LI D, ZHOU Y M, et al. Effects of receptor for advanced glycation endproducts on microvessel formation in endometrial cancer[J]. BMC Cancer, 2016, 16(1): 93.
